IV LENS / INFUSION PHARMACOKINETICS
NAD IV Therapy: Intravenous NAD+ in the Research Literature
What the infusion studies measured — plasma NAD+ undetectable for the first two hours, multi-day protocols, and small cognition and addiction pilots — read against an unapproved, compounded status.
In plain English
NAD IV therapy is an intravenous drip of NAD+ (the cell's energy-handling helper molecule) given over several hours, usually in a wellness clinic. Two things are worth knowing up front. First, the controlled evidence is the thinnest of any way of taking NAD+ — mostly small pilots, not large trials. Second, the pharmacokinetics (how the body handles the dose over time) are surprising: when researchers infused NAD+ and measured the blood, the NAD+ itself was undetectable for the first couple of hours. It is processed fast. This page reads those studies; it is not medical advice and recommends no treatment.
What Happens During an NAD+ Infusion (Pharmacokinetics)
The best-characterized fact about an NAD+ infusion is its pharmacokinetics, and they are counterintuitive. In a pilot infusing 750 mg over 6 hours in healthy men, plasma NAD+ was undetectable for roughly the first 2 hours and rose only in the final hours, while urinary methylated nicotinamide metabolites increased throughout — evidence that infused NAD+ undergoes extensive extracellular metabolism before plasma NAD+ itself climbs [6]. In other words, much of an IV NAD+ dose is broken down and routed into downstream metabolites rather than circulating as intact NAD+. This rapid clearance is why infusion protocols run over hours, and why the IV route's measurable persistence in blood is far lower than the days-to-weeks NAD+ elevation oral precursors produce [3][4].
When should you inject NAD+? What the protocols describe
Published IV protocols describe multi-day infusion courses rather than single sessions. The cognition pilot used 750 mg/day over several hours for 5 consecutive days [9]; the historical addiction literature describes 500-1000 mg IV NAD+ daily for about 4 days followed by maintenance dosing [8]; and the pharmacokinetic study used a single 750 mg infusion over 6 hours [6]. These timing details come from study protocols and are described here as research, not as dosing guidance for any person. The infusion rate matters for tolerability, covered below.
What the IV cognition and addiction pilots reported
IV NAD+ has a small cluster of human findings, all preliminary. A pilot of five daily 750 mg infusions reported statistically significant improvement on 6 of 8 neuropsychological tests in the NAD+ group versus 2 of 8 in the saline group [9]. In 50 treatment-resistant substance-use-disorder patients, IV NAD+ with enkephalinase inhibition was associated with significant reductions in craving (p = 1.06e-9), anxiety (p = 5.49e-7), and depression (p = 1.76e-4) [7]. A narrative review situates these within a long history — back to a 1961 case series — while stating that IV NAD+ remains unapproved by the FDA and that the field needs rigorous randomized trials before drawing conclusions [8]. The honest summary: real signals, weak controls, and no approved indication.
Tolerability and the IV-versus-NR comparison
Tolerability is where the IV route's costs show up. The 750 mg pilot recorded mild infusion-related symptoms — chest tightness and abdominal discomfort — when the infusion rate was higher [6]. A 2026 real-world retrospective comparison made the contrast sharp: IV NAD+ (500 mg) was associated with moderate-to-severe gastrointestinal symptoms, elevated heart rate, and chest pressure, requiring mean infusion times of 97 minutes, while IV NR (500 mg) caused only mild tingling and required about 37 minutes on average [15]. Infusion-related symptoms in that comparison resolved on completion, with no serious adverse events reported. Run too fast, IV NAD+ provokes symptoms; run slow, it takes a long time.
Status: unapproved, compounded, evidence-limited
NAD IV therapy is not an FDA-approved treatment. It is a compounded wellness therapy, and across reviews the controlled human evidence for IV NAD+ is the weakest of all routes [8][14]. A 2025 Nature Metabolism review of NAD+ precursor evidence in aging concluded that human efficacy for hard clinical endpoints remains preliminary and that tissue-specific NAD+ data are sparse — a verdict that applies with even more force to the thinner IV literature [14]. None of NAD+, NMN, NR, or nicotinamide is prohibited by WADA. This page documents the research; it endorses no clinic and no product.
Does NAD IV actually work?
A 6-hour IV NAD+ pilot found plasma NAD+ undetectable for the first 2 hours with extensive extracellular metabolism [6]; small pilots report cognitive improvements [9], but the controlled human evidence base for IV NAD+ is the weakest of all routes [8]. "Actually works" is not something the current literature can confirm for hard endpoints.
When should you inject NAD+?
Published IV protocols describe multi-day infusion courses — for example, 750 mg/day over several hours for several consecutive days [9], or 500-1000 mg/day for about 4 days then maintenance in the historical addiction literature [8]. Timing details come from study protocols and are described here as research, not as dosing guidance for any individual.